However, the role of stk33 in KRAS-dependent cancer cells remains disputed because other research groups were not able to find a correlation between the knockdown or inhibition of stk33 and KRAS-dependent cancer cell survival, neither using RNAi nor small molecule inhibitors [16–19]. Here, KRAS is linked to cancer.